SWEETLEAD: an In Silico Database of Approved Drugs, Regulated Chemicals, and Herbal Isolates for Computer-Aided Drug Discovery
暂无分享,去创建一个
Vijay S. Pande | V. Pande | Paul A. Novick | Oscar F. Ortiz | Jared Poelman | Amir Abdulhay | Jared Poelman | Amir Y. Abdulhay
[1] Charles C. Persinger,et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.
[2] R. W. Hansen,et al. The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.
[3] Joel Dudley,et al. Exploiting drug-disease relationships for computational drug repositioning , 2011, Briefings Bioinform..
[4] Heine H. Hansen. List of drugs , 2008 .
[5] Shyam Sundar,et al. Injectable paromomycin for Visceral leishmaniasis in India. , 2007, The New England journal of medicine.
[6] Yanli Wang,et al. PubChem: Integrated Platform of Small Molecules and Biological Activities , 2008 .
[7] D. Wechsler,et al. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome , 2009, British journal of haematology.
[8] Anthony Nicholls,et al. Essential considerations for using protein-ligand structures in drug discovery. , 2012, Drug discovery today.
[9] Kui Xu,et al. Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases , 2011, Briefings Bioinform..
[10] Laetitia Martin-Chanas,et al. Identify drug repurposing candidates by mining the Protein Data Bank , 2011, Briefings Bioinform..
[11] Ruili Huang,et al. The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.
[12] Hitoshi Iba,et al. Classification of Gene Expression Data by Majority Voting Genetic Programming Classifier , 2006, 2006 IEEE International Conference on Evolutionary Computation.
[13] P. Sanseau,et al. Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.
[14] Detrusor overactivity successfully treated with duloxetine , 2007, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.
[15] Igor Goryanin,et al. A semi-automated genome annotation comparison and integration scheme , 2013, BMC Bioinformatics.
[16] Alexander A. Morgan,et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.
[17] David S. Wishart,et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets , 2007, Nucleic Acids Res..
[18] Judith D. Cohn,et al. Genome Majority Vote Improves Gene Predictions , 2011, PLoS Comput. Biol..
[19] J. Languillon,et al. WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients. , 1971, Bulletin of the World Health Organization.
[20] G. Muirhead,et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. , 1996, International journal of impotence research.
[21] Gisbert Schneider,et al. Computer-based de novo design of drug-like molecules , 2005, Nature Reviews Drug Discovery.
[22] E. Estey,et al. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia , 2003, Cancer.
[23] Mark McGann,et al. FRED and HYBRID docking performance on standardized datasets , 2012, Journal of Computer-Aided Molecular Design.
[24] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.
[25] Shuichi Hirono,et al. Comparison of Consensus Scoring Strategies for Evaluating Computational Models of Protein-Ligand Complexes , 2006, J. Chem. Inf. Model..
[26] Mark A. Murcko,et al. Virtual screening : an overview , 1998 .
[27] M. Kanehisa. A database for post-genome analysis. , 1997, Trends in genetics : TIG.
[28] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[29] Antony J. Williams,et al. ChemSpider:: An Online Chemical Information Resource , 2010 .
[30] Russ B. Altman,et al. PharmGKB: the Pharmacogenetics Knowledge Base , 2002, Nucleic Acids Res..
[31] David S. Wishart,et al. Biospider: A Web Server for Automating Metabolome Annotations , 2007, Pacific Symposium on Biocomputing.
[32] G. Oliva,et al. Virtual screening and its integration with modern drug design technologies. , 2008, Current medicinal chemistry.
[33] Joel Lexchin,et al. The cost of drug development: a systematic review. , 2011, Health policy.
[34] David A. Dixon,et al. Annual reports in computational chemistry , 2007 .
[35] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[36] Thomas Girke,et al. ChemMine. A Compound Mining Database for Chemical Genomics1 , 2005, Plant Physiology.
[37] Wei Tang,et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. , 1997, Blood.
[38] Michael Darsow,et al. ChEBI: a database and ontology for chemical entities of biological interest , 2007, Nucleic Acids Res..